Microbiologic Cure with a Simplified Dosage of Intravenous Colistin in Adults: A Retrospective Cohort Study

References

• Katip W, Uitrakul S, Oberdorfer P. A Comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients: a propensity score-matched analysis. Antibiotics. 2020;9(10):647. doi:10.3390/antibiotics9100647
   Web of Science ®Google Scholar
• Suwantarat N, Carroll KC. Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia. Antimicrob Resist Infect Control. 2016;5:15. doi:10.1186/s13756-016-0115-6
   PubMed Web of Science ®Google Scholar
• Johns Hopkins Aramco Healthcare. Saudi: Antibiogram reports, 2023. Available from: https://insite.jhah.com/orgs/SamsoMembers/Lists/Infection%20Control%202011/AllItems.aspx . Accessed March 2, 2023.
   Google Scholar
• Shi H, Lee JS, Park SY, et al. Colistin plus carbapenem versus colistin monotherapy in the treatment of carbapenem-resistant Acinetobacter baumannii pneumonia. Infect Drug Resist. 2019;12:3925–3934. doi:10.2147/IDR.S234211
   PubMed Web of Science ®Google Scholar
• Martis N, Leroy S, Blanc V. Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections: a narrative review for the clinician. J Infect. 2014;69(1):1–12. doi:10.1016/j.jinf.2014.03.001
   PubMed Web of Science ®Google Scholar
• National Institute for Healthcare Excellence. UK: NICE impact antimicrobial resistance; 2018. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/Into-practice/measuring-uptake/NICEimpact-antimicrobial-resistance.pdf. Accessed August 22, 2022.
   Google Scholar
• Haseeb A, Farida HS, Al Ghamdi S, et al. Dose optimization of colistin: a systematic review. Antibiotics. 2021;10(12):1454. doi:10.3390/antibiotics10121454
   Google Scholar
• FDA. Coly-Mycin (Colistimethate) [Package Insert]. Chestnut Ridge, NY: Par Pharmaceutical (per FDA); 2017.
   Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39. doi:10.1002/phar.2209
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Polymyxin-containing medicines; 2018. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/polymyxin-containing-medicines. Accessed May 24, 2023.
   Google Scholar
• Tsala M, Vourli S, Georgiou P-C, et al. Exploring colistin pharmacodynamics against Klebsiella pneumoniae: a need to revise current susceptibility breakpoints. J Antimicrob Chemother. 2018;73(4):953–961. doi:10.1093/jac/dkx522
   PubMed Web of Science ®Google Scholar
• Gontijo AVL, Cavalieri AVG. Optimal control for colistin dosage selection. J Pharmacokinet Pharmacodyn. 2021;48(6):803–813. doi:10.1007/s10928-021-09769-6
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother. 2008;61(3):636–642. doi:10.1093/jac/dkm511
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Friberg L, Pontikis K, et al. Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients. Antimicrob Agents Chemother. 2015;59(12):7240–7248. doi:10.1128/AAC.00554-15
   PubMed Web of Science ®Google Scholar
• Plachouras D, Karvanen M, Friberg S, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother. 2009;53(8):3430–3436. doi:10.1128/AAC.01361-08
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Li J, Nation RL. Dosing of colistin-back to basic PK/PD. Curr Opin Pharmacol. 2011;11(50):464–469. doi:10.1016/j.coph.2011.07.004
   PubMedGoogle Scholar
• Ordooei Javan A, Shokouhi S, Sahraei Z, Salamzadeh J, Azad Armaki S. Nephrotoxicity of high and conventional dosing regimens of colistin: a randomized clinical trial. Iran J Pharm Res. 2017;16(2):781–790.
   PubMed Web of Science ®Google Scholar
• Alshaya AI, Bin Saleh K, Aldhaeefi M, et al. Colistin loading dose in septic patients with Gram negative infections. Infect Drug Resist. 2022;15:2159–2166. doi:10.2147/IDR.S361244
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349–358. doi:10.1093/cid/cit253
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii. Int J Infect Dis. 2020;97:391–395. doi:10.1016/j.ijid.2020.05.100
   PubMed Web of Science ®Google Scholar
• Kellum JA, Lameire N, Aspelin P. Kidney Disease: improving Global Outcomes (KDIGO). Acute Kidney Injury Work Group. KDIGO clinical practice guidelines for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.
   Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi:10.1159/000180580
   PubMed Web of Science ®Google Scholar
• Winter MA, Guhr KN, Berg GM. Impact of Various Body Weights and Serum Creatinine Concentrations on the Bias and Accuracy of the Cockcroft-Gault Equation. Pharmacotherapy. 2012;32:604–612. doi:10.1002/j.1875-9114.2012.01098.x
   PubMed Web of Science ®Google Scholar
• Humphries RM, Abbott AN, Hindler JA. Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories. J Clin Microbiol. 2019;57(6):e00203–19. doi:10.1128/JCM.00203-19
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Meropenem Breakpoints for Acinetobacter Spp. 1st. CLSI document MR03Ed1E; 2019.
   Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Polymyxin Breakpoints for Enterobacterales, Pseudomonas Aeruginosa, and Acinetobacter Spp. 2nd. CLSI document MR01Ed2E; 2020.
   Google Scholar
• Lambden S, Laterre PF, Levy MM, et al. The SOFA score-development, utility and challenges of accurate assessment in clinical trials. Crit Care. 2019;23(1):374. doi:10.1186/s13054-019-2663-7
   PubMed Web of Science ®Google Scholar
• Parchem NL, Bauer KA, Cook CH, et al. Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant Gram-negative pneumonia. Eur J Clin Microbiol Infect Dis. 2016;35(9):1433–1439. doi:10.1007/s10096-016-2681-1
   PubMed Web of Science ®Google Scholar
• Rosner B. Estimation of sample size and power for comparing two binominal proportions. In: Fundamentals of Biostatistics. 7th ed. Boston, MA, USA: Brooks/Cole; 2011:381–383.
   Google Scholar
• Chew KL, La MV, Lin RTP, et al. Colistin and Polymyxin B Susceptibility Testing for Carbapenem-Resistant and mcr-Positive Enterobacteriaceae: comparison of Sensititre, MicroScan, Vitek 2, and Etest with Broth Microdilution. J Clin Microbiol. 2017;55(9):2609–2616. doi:10.1128/JCM.00268-17
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Mavroudis AD, Georgiou M, et al. Intravenous plus inhaled versus intravenous colistin monotherapy for lower respiratory tract infections: a systematic review and meta-analysis. J Infect. 2018;76(4):321–327. doi:10.1016/j.jinf.2018.02.002
   PubMed Web of Science ®Google Scholar
• Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care. 2003;7(5):R78–83. doi:10.1186/cc2358
   PubMed Web of Science ®Google Scholar
• Vandijck DM, Reynvoet E, Blot SI, Vandecasteele E, Hoste EA. Severe infection, sepsis and acute kidney injury. Acta Clin Belg. 2007;62 Suppl 2:332–336. doi:10.1179/acb.2007.075
   PubMed Web of Science ®Google Scholar
• Dewi RS, Radji M, Andalusia R. Evaluation of Antibiotic Use among Sepsis Patients in an Intensive Care Unit: a cross-sectional study at a referral hospital in Indonesia. Sultan Qaboos Univ Med J. 2018;18(3):e367–73. doi:10.18295/squmj.2018.18.03.017
   PubMedGoogle Scholar
• Timsit JF, de Kraker M, Sommer H, et al. Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE’s STAT-Net. Intensive Care Med. 2017;43(7):1002–1012. doi:10.1007/s00134-017-4802-4
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Saffioti C, Losito AR, et al. Use of colistin in adult patients: a cross-sectional study. J Glob Antimicrob Resist. 2020;20:43–49. doi:10.1016/j.jgar.2019.06.009
   PubMed Web of Science ®Google Scholar
• Ehrmann S, Luyt CE. Optimizing aerosol delivery of antibiotics in ventilated patients. Curr Opin Infect Dis. 2020;33(2):197–204. doi:10.1097/QCO.0000000000000633
   PubMed Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Antimicrobial-Resistant Treatment Guidance: gram-Negative Bacterial Infections. Infectious Diseases Society of America 2023; Version 3.0. Available from: https://www.idsociety.org/practice-guideline/amr-guidance/. Accessed June 12, 2023.
   Google Scholar
• Boisson M, Jacobs M, Grégoire N, et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother. 2014;58(12):7331–7339. doi:10.1128/AAC.03510-14
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400. doi:10.1016/S1473-3099(18)30099-9
   PubMed Web of Science ®Google Scholar
• Kaye KS, Marchaim D, Thamlikitkul V, et al. Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms. NEJM Evid. 2022;2(1):EVIDoa2200131. doi:10.1056/EVIDoa2200131
   Google Scholar
• Zhang P, Hu H, Shi Q, et al. The Effect of β-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniae [published online ahead of print, 2023 Feb 16]. Antimicrob Agents Chemother. 2023:e0127922. doi:10.1128/aac.01279-22
   PubMed Web of Science ®Google Scholar
• Marner M, Kolberg L, Horst J, et al. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients. Microbiol Spectr. 2023;11(1):e0443722. doi:10.1128/spectrum.04437-22
   PubMedGoogle Scholar
• Giani T, Arena F, Vaggelli G, et al. Large Nosocomial Outbreak of Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniae Traced to Clonal Expansion of an mgrB Deletion Mutant. J Clin Microbiol. 2015;53(10):3341–3344. doi:10.1128/JCM.01017-15
   PubMed Web of Science ®Google Scholar
• Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013;19(1):E23–30. doi:10.1111/1469-0691.12070
   PubMed Web of Science ®Google Scholar
• Marchaim D, Chopra T, Pogue JM, et al. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother. 2011;55(2):593–599. doi:10.1128/AAC.01020-10
   PubMed Web of Science ®Google Scholar
• Antoniadou A, Kontopidou F, Poulakou G, et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother. 2007;59(4):786–790. doi:10.1093/jac/dkl562
   PubMed Web of Science ®Google Scholar
• Sharma S, Banerjee T, Kumar A, et al. Extensive outbreak of colistin resistant, carbapenemase (blaOXA-48, blaNDM) producing Klebsiella pneumoniae in a large tertiary care hospital, India. Antimicrob Resist Infect Control. 2022;11(1). doi:10.1186/s13756-021-01048-w
   PubMedGoogle Scholar
• Dickstein Y, Lellouche J, Schwartz D, et al. Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms. Clin Infect Dis. 2020;71(10):2599–2607. doi:10.1093/cid/ciz1146
   PubMed Web of Science ®Google Scholar
• Almutairi MM. Synergistic activities of colistin combined with other antimicrobial agents against colistin-resistant Acinetobacter baumannii clinical isolates. PLoS One. 2022;17(7):e0270908. doi:10.1371/journal.pone.0270908
   PubMed Web of Science ®Google Scholar
• Bir R, Gautam H, Arif N, et al. Analysis of colistin resistance in carbapenem-resistant Enterobacterales and XDR Klebsiella pneumoniae. Ther Adv Infect Dis. 2022;9:20499361221080650. doi:10.1177/20499361221080650
   Web of Science ®Google Scholar
• Zilberberg MD, Kollef MH, Shorr AF. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: a survey study. J Hosp Med. 2016;11(1):21–26. doi:10.1002/jhm.2477
   PubMed Web of Science ®Google Scholar
• Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care. 2011;1(1):30. doi:10.1186/2110-5820-1-30
   PubMedGoogle Scholar